CVS Restores Lilly Obesity Drug to Formularies After Prior Removal

CVS Health has returned Eli Lilly's obesity medication to its formularies after previously removing it. This formulary reinstatement affects Medicaid managed care organizations that contract with CVS Caremark for pharmacy benefit management services, potentially expanding access to GLP-1 medications for Medicaid enrollees. The decision reverses a prior coverage restriction and may influence pharmacy spending and prior authorization protocols. Managed care plans should review their pharmacy contracts and assess budget impact from potential increased utilization of high-cost obesity treatments.

Pharmacy · Managed Care